Apparatus for Improved Transfection and / or intracellular delivery efficiency of an Agent into a Eukaryotic Cell and / or Protein Expression and Method of Use Thereof

Abstract

A method and apparatus for improving transfection efficiency and/or an intra-cellular delivery process in one or more eukaryotic cells is provided. The method includes providing at least one naked agent suitable for transfection and/or intra-cellular delivery. Introducing the at least one naked agent to one or more eukaryotic cells to form a mixture or transfection mixture and allowing the mixture or transfection mixture to undergo a transfection process or intra-cellular delivery process to form one or more transfected or treated eukaryotic cells. The method includes directing pulsed electromagnetic signals provided at any or any combination of a pre-determined frequency, at a pre-determined pulse rate, or at a pre-determined power, at the at least one a naked agent at step (a) prior to creating the mixture or transfection mixture, at the mixture or transfection mixture in step (b), at the mixture or transfection mixture in step (c) and/or at the transfected or treated cell mixture after step (c).

Claims

1. A method of improving transfection efficiency and/or intra-cellular delivery in eukaryotic cells, said method including the steps of: a) providing at least one naked agent suitable for transfection and/or intra-cellular delivery in one or more eukaryotic cells; b) introducing the at least one naked agent to one or more eukaryotic cells to form a mixture or transfection mixture; c) allowing the mixture or transfection mixture to undergo a transfection process or intra-cellular delivery process to form one or more transfected or treated eukaryotic cells; characterised in that the method includes the step of directing pulsed electromagnetic signals provided at any or any combination of a pre-determined frequency, at a pre-determined pulse rate, or at a pre-determined power, at the at least one naked agent at step a) prior to creating the mixture or transfection mixture, at the mixture or transfection mixture in step b), at the mixture or transfection mixture in step c) and/or at the transfected or treated eukaryotic cells after step c).

2. The method of claim 1 wherein the at least one naked agent is any agent suitable for transfection and/or intra-cellular delivery and/or any or any combination of nucleic acid is deoxyribonucleic acid (DNA), ribonucleic acid (RNA), a combination of DNA and RNA, mRNA, tRNA, siRNA, or miRNA; a pharmaceutical and/or therapeutic agent or compound; an anthracycline drug or doxorubicin; an agent of therapeutic and/or pharmaceutical interest, a small molecule or small molecular material of less than 5 Kilodaltons; a large molecule or large molecular material equal to or greater than 5 Kilodaltons; one or more proteins, vaccine, one or more antibodies; an organic agent; or is or includes one or more expression vectors.

3-4. (canceled)

5. The method of claim 1, wherein the eukaryotic cells are suspended in solution and/or are adhered to a substrate; and/or the eukaryotic cells are immortal cells; the cells have been derived from the tissue of a human and/or animal subject; or the cells have been derived from a human and/or animal subject and comprise T-cells, lymphocytes, granulocytes, and or macrophages.

6. (canceled)

7. The method of claim 1, wherein the method includes the step of mixing the at least one agent with one or more carrier agents and/or solubilising agents.

8-9. (canceled)

10. The method of claim 1, wherein when the at least one naked agent is or includes nucleic acid, and the transfection process results in transient expression; or wherein at least one naked agent is or includes nucleic acid, and transfection process results in stable expression; the method further comprises the steps of isolating one or more of the eukaryotic cells after the transfection process, testing expression level of one or more peptides encoded by the at least one naked agent in the one or more isolated eukaryotic cells or progeny thereof, and selecting one or more isolated eukaryotic cells or progeny thereof based upon the expression level.

11. The method of claim 1, wherein the step of directing pulsed electromagnetic signals takes place for a pre-determined period of time; or wherein the step of directing pulsed electromagnetic signals takes place for a pre-determined period of time and the time is approximately 15 minutes when the pulsed electromagnetic signals are directed at the at least one naked agent; and/or is approximately 1-4 hours when the pulsed electromagnetic signals are directed at the mixture or transfection mixture during or after transfection and/or intra-cellular delivery.

12. (canceled)

13. The method of claim 1, wherein the pulsed electromagnetic signals are generated by one or more electronic devices, and wherein the one or more electronic devices include transmission means or one or more electronic transmission chips for generating and/or transmitting the pulsed electromagnetic signals therefrom in use; wherein each electronic device includes a single transmission means or electronic transmission chip, or each electronic device includes a plurality of transmission means or electronic transmission chips, optionally wherein the electronic device includes a plurality of transmission means or electronic transmission chips and each of said transmission means or electronic transmission chips are arranged a spaced distance apart from one another such that said distance apart equals approximately half of the wavelength of the pulsed electromagnetic signals; or wherein the electronic device includes at least one transmission means or electronic transmission chip per 105 to 115 cm.sup.2 of a surface of a housing of said device, or of a surface of one or more items to be placed upon the electronic device in use; or wherein the electronic device includes six transmission means or electronic transmission chips and said chips are arranged a spaced distance apart from each other in the device such that one transmission means or electronic transmission chip is directed at four wells of a twenty four well plate when said plate is positioned in, on or relative to said electronic device in use.

14. (canceled)

15. The method of claim 1, wherein the distance between the transmission means and one or more items receiving the pulsed electromagnetic signals in use is approximately 25 cm or less, approximately 20 cm or less, approximately 15 cm or less, approximately 10 cm or less, approximately 5 cm or less, or equal or approximately equal to 1 cm or less.

16. The method of claim 1, wherein the pre-determined frequency of the pulsed electromagnetic signals is approximately 2.45 GHz+/−50 MHz, is between approximately 2.2-2.6 GHz, is at approximately 2.4 GHz+/−50 MHz or is at approximately 2.45 GHz+/−50 MHz, and/or wherein the pre-determined pulse rate of the pulsed electromagnetic signals is approximately 50 Hz or less, approximately 25 Hz or less, approximately 15 Hz or less and/or has a duty cycle of less than 2%, and/or wherein each pulse of the pulsed electromagnetic signals lasts for between approximately 1 ms-20 ms or is approximately 1 ms, optionally wherein the rest period between each pulse of the pulsed electromagnetic signals last for approximately 66 ms or less, and/or wherein the pre-determined power provided by each transmission means or electronic transmission chip is approximately +2 dBm to +4 dBm, approximately 1 mW, approximately 2 mW or approximately 2.5119 mW, and/or wherein the pulsed electromagnetic signals are transmitted using Gaussian Frequency Shift Keying (GFSK) between 0.45 and 0.55.

17. (canceled)

18. The method of claim 13 wherein the one or more electronic devices include any or any combination of control means for controlling operation and/or one or more parameters of the electronic device and/or transmission means, power supply means for supplying electrical power to the one or more devices in use, one or more circuit boards, memory means for storing data thereon, user selection means for allowing a user to select the operation, one or more conditions and/or the one or more parameters of the device, or display means for displaying one or more settings, or options for settings.

19. The method of claim 18 wherein the one or more conditions or parameters of the devices that can be selected by a user include any or any combination of the signal frequency, the signal strength, signal or transmission power, the time periods of each pulse or rest period between signal pulses, the signal pulse rate of the pulsed electromagnetic signals.

20. Apparatus for providing improved transfection efficiency and/or intra-cellular delivery in eukaryotic cells, said apparatus including a housing, transmission means located in said housing and arranged to transmit pulsed electromagnetic signals provided at any or any combination of a pre-determined frequency, at a pre-determined pulse rate, or a pre-determined power in use, control means for controlling operation of at least the transmission means in use, and power supply means for providing electrical power to the transmission means and/or control means in use.

21. (canceled)

22. The apparatus according to claim 20, wherein the apparatus comprises at least one transmission means or electronic transmission chip per 105 to 115 cm.sup.2 of a surface of a housing of said device, or of a surface of one or more items to be placed upon the apparatus in use; and/or wherein the apparatus includes a plurality of transmission means or electronic transmission chips and said transmission means or electronic transmission chips are arranged a spaced distance apart such that said distance apart equals approximately half of the wavelength of the pulsed electromagnetic signals.

23. (canceled)

24. The apparatus according to claim 20, wherein the pre-determined frequency of the pulsed electromagnetic signals is between approximately 2.2-2.6 GHz, is approximately 2.4 GHz+/−50 MHz or is approximately 2.45 GHz+/−50 MHz, and/or wherein the pre-determined pulse rate of the pulsed electromagnetic signals is approximately 50 Hz or less, approximately 25 Hz or less, approximately 15 Hz or less and/or has a duty cycle of less than 2%, and/or wherein each pulse of the pulsed electromagnetic signals lasts for between approximately 1 ms-20 ms or is approximately 1 ms, and/or wherein a rest period between each pulse of the pulsed electromagnetic signals lasts for approximately 66 ms or less, and/or wherein the pre-determined power provided by each of said transmission means transmitting said pulsed electromagnetic signals is approximately +2 dBm to +4 dBm, approximately 1 mW, approximately 2 mW or approximately 2.5119 mW, and/or wherein the pulsed electromagnetic signals are transmitted using Gaussian Frequency Shift Keying (GFSK) between 0.45 and 0.55.

25-27. (canceled)

28. The apparatus of claim 20, wherein the housing comprises an outer casing, wherein at least the outer casing of the apparatus is coated and/or formed from a material to allow the apparatus to be implantable into a person's body or below a user's skin in use.

29. The apparatus of claim 20, wherein the apparatus is provided with at least one holding means or reservoir for holding or containing at least one naked agent which is to be transfected and/or is to undergo intra-cellular delivery into one or more eukaryotic cells or person in use.

30-31. (canceled)

Description

[0152] Specific embodiments of the invention are now described with reference to the accompanying drawings; wherein

[0153] FIGS. 1a and b illustrate views of apparatus in accordance with one embodiment of the invention;

[0154] FIGS. 2a and b illustrate views of apparatus in accordance with a second embodiment of the invention;

[0155] FIG. 3 illustrates a further embodiment of the invention;

[0156] FIGS. 4a and 4b illustrates elevations of a yet further embodiment of the present invention;

[0157] FIGS. 5a and 5b illustrate a trial utilising the invention in one embodiment;

[0158] FIG. 6 illustrates apparatus in one embodiment of the present invention in which the electronic device includes an array of 6 transmitter chips, together with an example of a twenty-four well plate that can be used with the electronic device in one example;

[0159] FIG. 7 shows a western blot from an experiment according to the present invention;

[0160] FIG. 8 shows a further western blot from an experiment according to the present invention.

[0161] In a first embodiment of the present invention there is provided apparatus 1 in the form of an electronic device that can be used for improving transfection efficiency and/or intra-cellular delivery of one or more agents in eukaryotic cells, for providing one or more therapeutic methods of treatment to a patient, for increasing delivery of a pharmaceutical and/or therapeutic agent into a patient, for increasing and/or decreasing gene expression, protein expression and/or the like.

[0162] The device is capable of emitting pulsed electromagnetic signals at a pre-determined frequency, at a pre-determined pulse rate, at a pre-determined power level and for a pre-determined period of time. The pre-determined parameters can be pre-set by the manufacturer or can be user selectable as required. The technology used in the apparatus is referred to hereinafter as the “pulsed technology according to the present invention”.

[0163] The apparatus 1 includes a housing 2, which includes a pulsed signal transmission system. In particular, in this example, the pulsed signal transmission system includes a circuit board 7 with transmission means in the form of an electronic transmission chip 4, typically provided as part of an integrated circuit, which allows the transmission of pulsed electromagnetic signals when the device is operational in use.

[0164] In one example, the housing can be in the form of a laboratory transfection plate including a base surface 3, an upper surface 11 opposite to base surface, and one or more side walls 13 located between the upper and base surfaces 3, 11.

[0165] Control means in the form of a control unit 10 can be provided to allow the selective operation of the apparatus 1. A memory device 6 is provided to allow data, one or more operating parameters, software and/or the like to be stored and retrieved when necessary. The control unit preferably includes micro-processing means to allow processing of data and/or the like.

[0166] The apparatus 1 could also include one or more power cells 10 to provide electrical power to the apparatus. A rechargeable facility can also optionally be provided to allow the power cells to be recharged from a remote power source rather than having to be replaced.

[0167] It will be appreciated that the housing 2 may be provided in any suitable form for its intended use and can be provided with engagement means to allow the same to be located with, for example an interior or exterior of a container in which the cells to be treated are located. Alternatively, the housing may be formed as part of a container in which the cells to be treated are located. Alternatively still, the upper surface 11 can provide a planar or flat surface on which a container in which the cells are to be treated or located can be placed. Yet further still, a recess could be defined in the upper surface 11 of the housing for stably supporting the placement of a container in the form of, for example, a cell culture flask, petri dish or other cell culture container, so that the housing 2 is located underneath the container and the container is supported in the recess.

[0168] The electronic transmission chip 4 is arranged in the housing 2 to emit the pulsed electromagnetic signals from the apparatus 1 in a particular direction or directions use. The direction of transmission of the pulsed electromagnetic signals will typically depend on what purpose the apparatus 1 is being used for. For example, if the apparatus 1 is being used as a laboratory transfection plate, the signals are typically directed through upper surface 11 towards a container locatable on said upper surface in use. If the apparatus is being used for wearing by a user, the signals are typically directed through base surface 3 towards the user.

[0169] In one embodiment of the present invention, the electronic transmission chip is arranged in the housing 2 such that it is spaced less than 5 cm from the surface of the housing 2 that is to be brought into contact with a user's skin or a cell reservoir in use, and preferably approximately 1 cm. This allows the electromagnetic signals emitted from the chip to be directed to the eukaryotic cells of the patient or in the cell reservoir in use.

[0170] The apparatus of the present invention is designed to be used at room temperature (i.e. approximately 20° C.), in temperatures colder than room temperature, such as for example in a refrigeration unit, and/or can be used at temperatures above room temperature, such as for example in an incubator unit or in a patient's body.

[0171] In one embodiment, the control unit 10 is programmed to control the transmission chip to allow it to emit pulsed electromagnetic signals at a frequency of 2.45 GHz+/−50 MHz, at a pulsed frequency of 15 Hz and at a power of approximately 2 mW. It will be appreciated that the parameters associated with the pulsed electromagnetic signals can be adjusted and/or be user selectable as required. For example, the time for which the pulsed electromagnetic signals are emitted can be selected by the user if required. In addition, the power can be adjusted, although it typically remains in the milliwatt range so as to avoid over energising the cells contained within the container 16 in use. In one example, the pulsed signals last for 1 ms and the rest period between signals is 66 ms. This provides a duty cycle of less than 2%.

[0172] In one example, the electromagnetic signals are RF signals using the Bluetooth LE protocol's advertising feature and are transmitted using GFSK between 0.45 and 0.55.

[0173] However, it should be noted that any frequency transmission in the Industrial, Medical and Scientific frequency bands (i.e. 2.4 to 2.4835 GHz, preferably 2.45 GHz+/−50 MHz) could be possible by the electronic apparatus in use.

[0174] In the illustrated example in FIG. 1a, selection means 5 are provided to allow the selection of a particular sequence of pulses, frequency, timing, and/or strength of the pulses in order to allow the apparatus to be configured according to a user's requirements.

[0175] In the embodiment shown in FIGS. 1a and 1b, the apparatus 1 is illustrated for positioning directly on the surface of a patient's skin 12. In this example, attachment means in the form of a band 14 is provided for detachably attaching the apparatus 1 to the user's body. More particular, band 15 passes around the patient's arm or limb so as to secure the housing 2 in the required location with respect to a portion of the patient's skin. Alternatively, the base surface 3 of the housing which is to contact with the skin can be provided with an adhesive material thereon to allow the same to be adhered to the patient's skin at the required location. When the apparatus 1 is operated in use, the pulsed electromagnetic signals 22 emitted from the housing 2 pass into at least a portion of the patient's skin, and possibly further into the tissue 24 and cells of the patient's body.

[0176] In another embodiment of the present invention, as shown in FIGS. 2a and 2b, the apparatus housing 2 is located on top of a drug-delivery “patch” 25 (sometimes referred to as a ‘transdermal patch’) which, in turn, is adhered to a portion of a user's skin 12. In this embodiment the pulsed electromagnetic signals 22 are emitted from the housing 2, are directed into the patch 25 and through the portion of the patch which includes the agent or drug 26 to the skin 12. The drug is delivered into the user's tissue and cells 24 by passing through the user's skin. Use of the pulsed electromagnetic signals enhances the absorption and uptake of the drug through the user's skin.

[0177] In another embodiment of the present invention, as shown in FIG. 3, the apparatus is provided as an implantable device. More particularly, the housing 2 of the apparatus provides a sterile outer casing which is implanted subcutaneously under the user's skin 12 and/or in the user's tissue 24. Once implanted, the apparatus emits the pulsed electromagnetic signals 22 therefrom. The implant is positioned so that the signals 22 are emitted in a desired direction towards, for example, a cancerous tumour 28.

[0178] In yet further embodiment of the present invention, as shown in FIGS. 4a and 4b, the apparatus is provided in the form of a pendant 36. In the illustration, the pendant is arranged to be worn on a chain 37 so as to position the pendant the level of the throat/upper chest 38 of the patient or person 39. The pulsed electromagnetic signals 22 are then directed from the pendant into the body of the wearer as indicated by arrow 41 of FIG. 4a. The face 43 of the pendant 36 is arranged to be locatable closest to the person when the pendant is worn at the required location.

[0179] In one example, the apparatus of the present invention could be worn so as to minimise viral replication and as a means to provide greater immunological protection to the wearer. Thus, in this embodiment, when the pendant 36 is worn at the level of throat/upper chest, a boost is provided to the immunity of this critical respiratory zone in the wearer.

[0180] Typically, in whichever embodiment, the apparatus of the present invention is provided at or adjacent a portion of the skin of a user which has been selected to provide a topical and focused treatment at a predetermined location.

[0181] For example, if the purpose of the apparatus is to provide a treatment for a cancerous tumour in a patient, the apparatus is located in the vicinity of, or is implanted into, a recognised cancerous tumour such as may be present, for example, in the liver, kidney, breast or bone. Alternatively, if the apparatus is to be provided to achieve a therapeutic benefit or to limit or prevent the possibility of infection, the apparatus can be located externally of the patient adjacent the portion of the patient's body at which therapeutic or preventative effect is believed to be most beneficial, such as at the throat region of the patient or person.

[0182] Thus, if the apparatus is located directly on the skin 12 of a patient, the pulsed electromagnetic signals are emitted through the skin and into the tumour to provide a change in condition of the tumour cells. If the apparatus is to be used in conjunction with a patch or other drug carrying item, such as for example as shown in FIGS. 2a and 2b, then the drug is enabled to pass through the patient's skin more easily than would conventionally be possible. The pulsed electromagnetic signals are thought to increase the size of the skin pores and allow greater space for the passage of the drug therethrough. Thus, pharmaceutical drugs or other agents can be delivered more efficiently and effectively using the present invention. In addition, pharmaceutical drugs or other agents which cannot currently be provided transdermally, can now be supplied into the body using the process of the present invention. The provision of the apparatus of the present invention enhances both delivery of the drug by increased skin permeability and provides a direct treatment benefit.

[0183] In an example of the invention illustrated in FIG. 5a, an active assembly was prepared comprising a “sandwich” arrangement of cell cultures and apparatus 1 in accordance with the invention for generating pulsed electromagnetic signals. A 500 ml culture vessel 32 containing colon cancer cells was placed underneath the housing 2 of the apparatus and a 500 ml culture vessel 34 containing healthy cells was placed on top of the apparatus.

[0184] A second, identical assembly of the culture vessels was prepared as shown in FIG. 5b but without the apparatus of the invention and this acted as a control.

[0185] In the performance of the test the two assemblies culture “stacks”, active and control, were placed in separate incubators at 37 degrees C. for 18 hours and in the active assembly the apparatus 1 was operated to generate electromagnetic signals 22 in both directions 40, 42 to pass through both vessels 32, 34 for at least periods of time during the said 18 hours.

[0186] The results were then assessed by microscopic observation and the p53 protein expression was analysed by Western Blot and spectrophotometry.

[0187] Microscopic examination showed distinct and major differences between the active and control cultures in terms of the numbers of cells and their condition. The healthy cells 34 in the active assembly showed dramatic growth and had clumped together in an effort to form tissue, whereas in the cancerous tissue 32 the cell growth had been interrupted.

[0188] Referring to FIG. 6, there is illustrated a further example of apparatus 102 for providing the pulsed electromagnetic signals according to a further embodiment. Whereas, some apparatus of the present invention can comprise a single electronic chip for transmission of the pulsed electromagnetic signals, FIG. 6 shows apparatus 102 that has an array of six electronic chips 104 for transmission of the pulsed electromagnetic signals. Although FIG. 3 shows the electronic chips 104 as being on top of the apparatus 102, this is just shown like this for clarity and the chips 104 are actually contained within the apparatus 102. The housing 204 comprises a base 105, a top surface 107 opposite to the base 105 and side walls 109 located between the base 105 and top surface 107.

[0189] The six electronic chips 104 are provided a spaced distance apart in the apparatus 102. The spacing between the chips can be any required distance but, in one example, the chips are spaced apart such that when a 24 well cell plate 106 is located on upper surface 7 of the apparatus in use, one transmission chip 104 is located centrally of four of the wells. Thus, each electronic chip 102 directs pulsed electromagnetic signals to 4 wells per 24 well cell plate. An on/off operational switch 108 is provided on the apparatus 102 to move the apparatus between on and off conditions in use.

[0190] As a simplified overview, in one example, material comprising a combined dispersion of eukaryotic cells and naked nucleic acid (DNA, RNA or small segments of either) is contained in a suitable container such as a culture vessel, flask or dish which, in one embodiment is located on the 102 and pulsed electromagnetic signals are emitted from the apparatus and are directed through the wall of the container and into the material.

[0191] The pulsed technology of the present invention can be used on the naked agent(s) prior to transfection taking place, such as for example on the nucleic acid. The pulsed technology of the present invention can also be used, or alternatively be used, on the mixture or transfection mixture including the naked agent(s) and the eukaryotic cells. In addition, or alternatively still, the pulsed technology of the present invention can be used on the cells once transfection and/or intra-cellular delivery has taken place, and/or on eukaryotic cells which have not undergone transfection and/or intra-cellular delivery to increase protein expression in those cells.

[0192] In the following experiments used to exemplify the present invention, the same pulsed technology of the present invention has been used on the naked agent(s) prior to mixing with different eukaryotic cells lines, and/or on the eukaryotic cell lines mixed with the naked agent(s) during a transfection process and/or intra-cellular delivery process.

[0193] Human Colon Tumour (HCT) 116 cells (adherent cells) (ATCC, USA-ATCC® CCL-247™) were seeded at a density of 3×10.sup.5 cells per well in two CELLSTAR® 6-well plates (9.6 cm.sup.2) in a final volume of 5 mL Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher, USA)+10% Fetal Bovine Serum (FBS) (Hyclone, USA) 24 hours before treatment.

[0194] The naked agent used was Doxorubicin (0.25 μM) (Sigma Aldrich) in absolute ethanol and was given to the cells for a 1 hour treatment period and incubated at 37° C., at 5% CO.sup.2.

[0195] After treatment the media was removed and fresh media was added to the cells. One of the plates was incubated directly at 37° C., at 5% CO.sup.2 and the second plate was placed in a different incubator and pulsed using the pulsed technology of the present invention at 37° C., at 5% CO.sup.2.

[0196] Protein extracts were collected at 3 hours, 6 hours, 9 hours, 16 hours or 24 hours of treatment for analysis by SDS-page.

[0197] The following Western Blot protocol is set out in reference [5].

[0198] Preparation of Protein Extracts for Western Blot

[0199] 1. For protein extraction the cells were washed twice with ice-cold PBS and then lysed in NP-40 extraction buffer (50 mM Tris pH 7.5; 10% glycerol; 0.1% “NP-40 Alternative” (Merck Millpore, USA); 100 mM NaCl; 0.2 mM EDTA) supplemented with 1× Complete™ Protease Inhibitor Cocktail (Roche, Switzerland). Extracts were sonicated (20 seconds, 20% amplitude) and protein concentration was determined using BCA™ Protein Assay Kit (ThermoFisher Scientific, USA) according to the manufacturer's recommendations.

[0200] Western Blot Protocol

[0201] 1. Protein extracts (15/20 μg depending on the experiment) were supplemented with 0.1M dithiothreitol (DTT) and 1×LDS buffer (Invitrogen, USA) and were heated at 95° C. for 10 min before loading on NuPAGE 10% Bis-Tris polyacrylamide gels (Invitrogen, USA).

[0202] 2. Protein samples were separated by electrophoresis (100V) using 1×MOPS Running Buffer. Transfer of proteins was performed at 12V overnight onto a nitrocellulose membrane (Protran 0.1 μm from GE Healthcare, USA) in 1× Transfer Buffer supplemented with 20% methanol. 1× Transfer Buffer is prepared from 10× Wet blot solution containing 144 g of glycine and 30 g Tris-Base in a final volume of 1 L milli-Q water.

[0203] 3. Membranes were blocked for 30 min in 5% BSA diluted in PBS-0.1% Tween20 before being incubated overnight with a primary antibody (Mouse monoclonal antibody DO1). After a wash of 15 min in PBS-Tween20, membranes were incubated for 1 h with a corresponding secondary antibody (HRP conjugated Donkey anti Mouse). All secondary antibodies, conjugated with Horse Radish Peroxidase (HRP), were purchased from Jackson ImmunoResearch lab and used at 1:10000/1:15000 dilution (depending on the antibody) in 5% BSA-PBS-Tween20.

[0204] At the end of the incubation membranes were washed twice with PBS-Tween20 for 15 min followed by a final 10 min wash with PBS. The chemiluminescence signal was detected on Hyperfilm™ ECL (Cytiva, USA) using the Amersham ECL Western Blotting Detection System (Cytiva, USA).

[0205] Results

[0206] Referring to FIG. 7, it can be seen from the Western Blot that p53alpha—the main isoform of the p53 protein—was upregulated after treatment with the pulsed technology according to the present invention. The effect was observed as soon as 3 hours after the addition of the drug and was most evident 24 hours post-treatment. Other isoforms of p53 were also more upregulated under the effect of the pulsed technology according to the present invention following doxorubicin treatment, namely d133p53alpha, d133p53beta and d160p53beta.

[0207] In the Western Blot, γH2AX was used as a marker to ensure that if any effect was observed it was not caused due to ionising radiation. γH2AX's expression changes when ionising radiation is present, and since there is no observed change between the pulsed technology according to the present invention and the control arms, it was concluded that the pulsed technology of the present invention did not emit ionising radiation.

[0208] Ku80 was used as the loading control to ensure that equal concentrations of each sample was loaded onto each well. Equal concentrations of Ku80 make the rest of the bands in the Western Blot comparable.

[0209] Referring to FIG. 8, in another experiment, some cells were treated by the pulsed technology of the present invention and some cells received no pulsed technology of the present invention as a control for 5 days without the addition of doxorubicin. No change in p53alpha expression was observed. When 0.25 μM doxorubicin was added to the cells for 1 hour, the cells under the effect of the pulsed technology according to the present invention showed a significant overproduction of p53alpha compared to the control after 16 hours.

[0210] In conclusion, there is clear evidence that treating the cells with the pulsed technology according to the present invention increases the ability of the cells to uptake doxorubicin from the media as various p53 isoforms were upregulated more in the pulsed technology arm compared to the control arm. It can be concluded that this effect is not caused by ionising radiation as the radiation marker gH2AX remained unchanged between the pulsed technology arm and the control arm.

[0211] Therefore, the combined effect of enhanced delivery of anti-cancer drugs and the direct treatment of pulsed technology according to the present invention affects beneficially the regulation of replication via the p53 oncogene and improves cancer treatment. Moreover, the effect of the pulsed technology of the present invention on non-mutated p53 of healthy cells results in increased repair of these cells.

[0212] Although the above examples shows only the intra-cellular delivery of the naked agent in the form of Doxorubicin being significantly improved on exposure of the eukaryotic cells in the form of HCT 116 Cells and the Doxorubicin to the pulsed technology of the present invention, the Applicants fully expect and predict that the intra-cellular delivery of one or more naked agents other than Doxorubicin into one or more eukaryotic cells (using HCT 116 cells or other eukaryotic cells) will be significantly improved on exposure of the same to the pulsed technology of the present invention. The Applicants also fully expect and predict that the intra-cellular delivery of one or more naked agents will be further significantly improved when the at least one naked agent is exposed to the pulsed technology of the present invention prior to mixing with the one or more eukaryotic cells (either alone or in addition to exposing the mixture or transfection mixture to the pulsed technology of the present invention) and/or after the intra-cellular delivery and/or transfection step has taken place. These predictions and expectations are based on data already collected by the Applicants in their co-pending application claiming priority from British Patent Applications GB2004412.9, GB 2009296.1, GB2004411.1 and GB2009297.9, the content of which is incorporated herein by reference, which shows that the transfection efficiency of one or more transfection agents associated with amphiphilic constructs in eukaryotic cells is significantly improved when exposed to the pulsed technology of the present invention on a) the transfection mixture prior to the addition of the eukaryotic cells; b) the transfection complex including the transfection mixture and the eukaryotic cells, and/or c) during and/or after the transfection process. The data for these experiments is reproduced below to show support for the breadth of the claim set of the present application. The Applicant's predict the same or similar mechanism of improvement of transfection efficiency and/or intra-cellular delivery when an agent is associated with an amphiphilic construct as when a “naked agent” (i.e. not associated with an amphiphilic construct) is used. This is because the pulsed electromagnetic waves or signals according to the present invention are thought to be sufficient to rotate H.sub.2O periodically around its dipole with relatively long rest or relaxation periods. The periodic rotation of H.sub.2O is thought to interrupt hydrogen bonding in the phospholipid bilayer or cell membranes of the eukaryotic cells. This periodic or intermittent low energy perturbation of the cell membranes is thus thought to stimulate increased interaction with the agent, some molecules and/or cell membranes and their environment, such as for example, the nucleic acid or agent with the cell membrane. The relatively long rest or relaxation period between the pulses of the pulsed electromagnetic signals is thought to be sufficient to maintain cellular integrity.

[0213] In the following experiments taken from the Applicant's co-pending patent application, the same pulsed technology of the present invention was used on a transfection mixture (transfection agent+amphiphilic construct) prior to mixing with different eukaryotic cells lines, and/or on eukaryotic cell lines mixed with the transfection mixture during a transfection process.

[0214] The nucleic acid used in the experiments comprised DNA plasmid material including a arginine vasopressin (AVP) promoter, a simian virus 40 (SV40) promoter, or an insulin like growth factor binding protection 3 (IGFBP3) promoter. A cytomegalovirus (Adluc) plasmid, a luciferase control vector (Renilla) plasmid or a Green Fluorescent Protein (GFP) plasmid were also used.

[0215] The amphiphilic constructs used in the experiments were either a transfection reagent containing cationic polymer (Turbofect™) (Thermo Fisher, USA), polyethylenimine (PEI) (Fisher Scientific, USA), or TransIT2020 (Mirus Bio, USA).

[0216] The cell lines used in the experiments were Chinese Hamster Ovary—K1 (CHO) cells (adherent cells) (ATCC, USA-ATCC® CCL-61™), Human Embryonic Kidney (HEK) 293 freestyle cells (suspension cells) (Thermo Fisher, USA), Human Colon Tumour (HCT) 116 cells (adherent cells) (ATCC, USA-ATCC® CCL-247™) or Jurkat E6 (suspension T-cells) (ECACC), UK).

[0217] In order to determine the efficiency of the cell transfection process using the above components, the luciferase activity or the amount of green fluorescent protein was measured using suitable equipment.

[0218] The DNA plasmid material chosen was complexed with the amphiphilic construct using known techniques to form a transfection mixture. In some experiments this transfection mixture was subjected to the pulsed technology of the present invention. The transfection mixture (with or without being exposed to pulsed technology) was then mixed in a dispersion of one of the mammalian cell lines in a suitable cell culture container to form a transfection complex. This cell culture container was then placed on the apparatus housing of the present invention and subjected to the pulsed technology as previously described for a predetermined period of time. The emission of the pulsed electromagnetic signals was then stopped and the material was allowed to reach equilibrium. In addition, control experiments were also conducted using the same material and mixing requirements identically but in the absence of the pulsed technology of the present invention.

[0219] A more detailed description of the methodology used in the experiments, the results and the findings are provided below.

[0220] Methodology

[0221] Experiment 1—Transfection of Adherent CHO K1 and HCT116 Cells Using Adluc and Renilla Plasmids and Using Either PEI or Turbofect as the Amphiphilic Construct

[0222] This experiment was undertaken to look at the effect of the pulsed technology of the present invention on the process of transfection in adherent Chinese Hamster Ovary (CHO) K1 cells (ATCC, USA) and HCT116 (Human Colon Cancer Cell Line) (ATCC, USA) using Adluc and Renilla Plasmids in either PEI (Fisher Scientific, USA) or Turbofect (Thermo Fisher, USA) amphiphilic constructs. The pulsed technology was applied to a) the cells and the transfection mixture (the transfection complex) during the transfection process only; and b) the transfection mixture prior to forming a transfection complex with the cells and then to the transfection complex during the transfection process.

[0223] Consumables

[0224] Opti-MEM™ I Reduced Serum Media (Thermo Fisher, USA)

[0225] Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher, USA)

[0226] Fetal Calf Serum (FCS) (Hyclone, USA)

[0227] 2×24 Well Plates Nunc (1.9 cm.sup.2/well) (Thermo Fisher, USA)

[0228] 200 ng of AdLuc plasmid/well (Luciferase expressing plasmid/DNA) (made by Dundee University, UK)

[0229] 2 ng Renilla plasmid/well (Luciferase expressing plasmid/DNA) (made by Dundee University, UK)

[0230] Alfa Aesar™ Polyethyleneimine, linear, M.W. 25,00 (PEI) (Fisher Scientific, USA)

[0231] Turbofect (Thermo Fisher, USA)

[0232] Method Steps

[0233] Control—Using PEI

[0234] 1. 650 μL of Opti-MEM media was mixed with 2.6 μg of AdLuc plasmid and 26 ng of Renilla plasmid in a first tube;

[0235] 2. 650 μL of Opti-MEM media was mixed with 7.88 μg of PEI in a second tube;

[0236] 3. The contents of the second tube was mixed in a dropwise manner to the first tube while gently vortexing until a final volume of 1.3 mL mixture was achieved using a Vortex-Genie 2, Model G560E, (Scientific Industries, USA);

[0237] 4. The transfection mixture was incubated for 15 minutes at room temperature (approx. 20° C.);

[0238] 5. 100 μL of this incubated transfection mixture was then dispensed into wells labelled A1-A6 on each of the two 24 well plates (Plates 1 and 2). This formed the transfection mixture.

[0239] Invention—with Pulsed Technology Using PEI on Transfection Mixture Prior to Transfection Complex Being Created

[0240] 1. Then, steps 1-3 above were repeated but at step 4—the mixture forming the transfection mixture was incubated for 15 minutes at room temperature (approx. 20° C.) by locating the first tube on a pulsed electromagnetic signal device according to the present invention. The pulsed device operates as described above (i.e. pulsed device operated at 2.45 GHz+/−50 MHz, at power 2 mW using a pulsed frequency of 15 Hz).

[0241] 2. 100 μL of this incubated pulsed transfection mixture was dispensed into wells labelled B1-B6 on each of the two 24 well plates (Plates 1 and 2);

[0242] Control—Using Turbofect [0243] 1. 650 μL of Opti-MEM media was mixed with 2.6 μg of AdLuc plasmid and 26 ng of Renilla plasmid in a first tube; [0244] 2. 13 μL of Turbofect was added and mixed by vortexing using a Vortex-Genie 2, Model G560E, (Scientific Industries, USA); [0245] 3. The transfection mixture was incubated for 15 minutes at room temperature (approx. 20° C.) [0246] 4. 100 μL of this incubated transfection mixture was dispensed into wells labelled C1-C6 on each of the two 24 well plates (Plates 1 and 2);

[0247] Invention—Using Turbofect with Pulsed Technology on Transfection Mixture Prior to the Transfection Complex being Created [0248] 1. Steps 1-2 above were repeated for the Turbofect Control. At step 3—the transfection mixture was incubated for 15 minutes at room temperature (approx. 20° C.) by locating the first tube on a pulsed electromagnetic signal device according to the present invention. The pulsed device operated at 2.45 GHz+/−50 MHz, at power 2 mW using a pulsed frequency of 15 Hz. [0249] 2. 100 μL of this incubated pulsed transfection mixture was dispensed into wells labelled D1-D6 on each of the two 24 well plates (Plates 1 and 2);

[0250] Cell Lines Added to Plates 1 and 2 [0251] For the Plates 1 and 2, a transfection complex was created by adding either CHO K1 cells or HCT116 cells into each well of the two 24 well plates at 2×10.sup.4 cells/well and then made up to a final volume of 600 μL of Dulbecco's Modified Eagle Medium (DMEM)+10% Fetal Calf Serum (FCS). In particular, A1-A3, B1-B3, C1-C3 and D1-D3 had CHO K1 cells added; A4-A6, B4-B6, C4-C6 and D4-D6 had HCT 116 Cells added; [0252] Plates 1 and 2 were incubated in an incubator at 37° C., 5% CO.sup.2 for 3 hours; [0253] In plate 1 there was no pulsed technology given to the transfection complex during the 3 hour incubation stage, whereas plate 2 was subjected to pulsed technology according to the present invention for 3 hours during the incubation stage. [0254] After 4 hours, the wells were topped up with DMEM containing Turbofect transfection reagent. [0255] The average value of the three wells for each experimental condition was measured and recorded. [0256] In some cases, the above experiment was undertaken using a first type of pulsed technology where only a single transmitter was provided in the pulsed device (Technique 1 pulsed technology). In some cases, the above experiment was undertaken using a second type of pulsed technology where an array of multiple transmitters was used in the pulsed device (Technique 2 pulsed technology). In particular, in experiments using the Type 2 pulsed technology, six transmitters were provided and each transmitter was arranged centrally or substantially centrally of four wells of a 24 well plate when the plate was located on the pulsed device.

[0257] Luciferase Assay Protocol—Using the Dual-Luciferase Reporter Assay System (Promega, USA)

[0258] Method Steps [0259] 1. 24 hours after the transfection experiments took place, the media was removed from the cells. [0260] 2. The cells were washed twice with Phosphate Buffered Saline (PBS). [0261] 3. 100 μL of 1× Passive Lysis Buffer (Promega, USA) was added to the cells. [0262] 4. The cells were incubated for 15 minutes at 37° C. while gently rocking on a Belly Dancer® Orbital Shaker (Sigma, Aldrich). [0263] 5. 10 μL of cells was taken from each well and placed in a white 96 well plate. [0264] 6. The cells were analysed with a Microplate Luminometer LB 96V (EG & G Berthold, Germany) using the Dual-Luciferase Assay System Protocol (Promega, USA). [0265] 7. The analysis was undertaken by injecting 30 μL Luciferase Assay Reagent II (Promega, USA) to measure firefly luciferase activity and then 30 μL Stop & Glo™ reagent to block firefly luciferase and measure renilla luciferase activity. [0266] 8. Lysed extracts were then kept at −20° C. to run Western Blots if required. [0267] 9. Transfection Efficiency in cells was undertaken by placing the cells in an Incucyte® Live Cell Analysis System (Essen Bioscience, USA) for 72-96 hours. Data was collected and analysed in Excel®.

[0268] Results for Experiment 1

[0269] Table 1 shows the results of the CHO K1 cell experiments where technique 1 pulsed technology was used with the Turbofect amphiphilic construct and associated methodology.

TABLE-US-00001 TABLE 1 (Technique 1 Pulsed Technology) Pulsed Technique 1 & Turbofect Control Technology Luminescence (a.u.) 40147 131502 Luminescence (a.u.) 62199 100925 Luminescence (a.u.) 94460 117862 Average Luminescence (a.u.) 65602 116763 % Increase in Pulsed Technology compared to Control - 178% Average Fold Increase in Pulsed Technology compared to Control - 1.8 T-test - 0.024

[0270] Table 2 shows the results of the CHO K1 cells experiments where technique 2 pulsed technology was used with the Turbofect amphiphilic construct and associated methodology.

TABLE-US-00002 TABLE 2 (Technique 2 Pulsed Technology) Pulsed Technique 1 & Turbofect Control Technology Luminescence (a.u.) 58615 94228 Luminescence (a.u.) 73946 184908 Luminescence (a.u.) 91469 242183 Average Luminescence (a.u.) 74676.67 173773 % Increase in Pulsed Technology compared to Control - 232.7% Average Fold Increase in Pulsed Technology compared to Control - 2.3 T-test - 0.044

[0271] Table 3 shows the results of the HCT 116 cells experiments where pulsed technology was used with the Turbofect amphiphilic construct and associated methodology.

TABLE-US-00003 TABLE 3 Pulsed Technique 1 & Turbofect Control Technology Luminescence (a.u.) 16794 23706 Luminescence (a.u.) 14626 24841 Luminescence (a.u.) 15555 16510 Average Luminescence (a.u.) 15658.33 21685.67 % Increase in Pulsed Technology compared to Control - 138.5% Average Fold Increase in Pulsed Technology compared to Control - 1.4 T-test - 0.044

[0272] With reference to Tables 1 and 2, the transfection efficiency in CHO K1 Cells associated with the Turbofect amphiphilic construct are shown for controls and pulsed technologies according to the present invention (Pulzar). Each condition contains three replicates. The amount of luminescence was measured for all cells as a measure of luciferase activity (i.e. transfection).

[0273] It can be seen that the transfection efficiency in CHO K1 cells using technique 1 pulsed technology was significantly improved compared to the control cells, with a t-test value of 0.024, an average fold increase of 1.8 and % increase of 178.0.

[0274] It can also be seen that the transfection efficiency in CHO K1 cells using technique 2 pulsed technology was significantly improved compared to the control cells, with a t-test value of 0.044, an average fold increase of 2.3 and % increase of 232.7.

[0275] Furthermore, it can be seen that experiments undertaken with technique 2 pulsed technology (i.e. the 6 electronic transmitter chip array) produced significantly better results than the experiments undertaken using technique 1 pulsed technology.

[0276] With reference to Table 3, the transfection efficiency in HCT 116 Cells associated with the Turbofect amphiphilic construct are shown for controls and pulsed technology according to the present invention (Pulzar). Each condition contains three replicates. The amount of luminescence was measured for all cells as a measure of luciferase activity.

[0277] It can be seen that the transfection efficiency in HCT 116 cells using pulsed technology was significantly improved compared to the control cells, with a t-test value of 0.044, a fold increase of 1.4 and % increase of 138.5.

[0278] Thus, it can be concluded that the pulsed technology of the present invention significantly increased the transfection efficiency in adherent CHO K1 cells and HCT 116 cells compared to when pulsed technology was not used. Furthermore, six electronic transmitters produced a further increase in transfection efficiency compared to where only a single electronic transmitter was used.

[0279] Experiment 2—Transfection of Adherent HCT Cells Using Either the IGFBP3 Promoter Containing Plasmid or the SV40 Promoter Containing Plasmid, and PEI as the Amphiphilic Construct

[0280] Experiment 2 was undertaken to look at the effect of the pulsed technology of the present invention on the process of transfection of adherent HCT116 (Human Colon Cancer Cell Line) (ATCC, USA) using the Adluc and Renilla Plasmids containing either the IGFBP3 promoter or the SV40 promoter in PEI (Fisher Scientific, USA) amphiphilic constructs. The methodology of Experiment 1 was followed for Experiment 2.

[0281] Results for Experiment 2

TABLE-US-00004 TABLE 4 Average Luceiferase Pulsed activity Control Technology Exp 1 1179 1753 (Replicate) 827 1918 1124 1865 Exp 2 1190 1732 (Replicate) 1831 2857 1325 2472 Average 1246 1099.5 St. Dev 330.616394 459.4809028 % Fold Increase = 168.4991974 t.test p < 0.004154274

[0282] Table 4 shows the results of the HCT 116 cells experiments for the IGFBP3 promoter using the PEI amphiphilic construct and associated methodology.

TABLE-US-00005 TABLE 5 Average Luceiferase Pulsed activity Control Technology Exp 1 9204 11682 (Replicate) 6769 12714 5370 13356 Exp 2 6291 9838 (Replicate) 15530 14261 7637 17011 Average 8466.833 13143.66667 St. Dev 3696.691138 2428.921626 % Fold Increase = 155.2371016 t.test p < 0.026953884

[0283] Table 5 shows the results of the HCT 116 cells experiments for the SV40 promoter using the PEI amphiphilic construct and associated methodology.

[0284] With reference to Tables 4 and 5, the transfection efficiency of DNA plasmids, containing either the IGFBP3 promoter or SV40 promoter, and associated with a PEI amphiphilic construct, in HCT 116 Cells are shown for controls and pulsed technologies according to the present invention (Pulzar). Two experiments were undertaken for each condition which are replicates of three. The amount of luminescence was measured for all cells as a measure of luciferase activity.

[0285] It can be seen that the transfection efficiency (shown by the IGFBP3 promoter) in HCT 116 cells using pulsed technology was significantly improved compared to the control cells, with a t-test value of 0.004 and % increase of 168.5.

[0286] It can be seen that the transfection efficiency (shown by the SV40 promoter) in HCT 116 cells using pulsed technology was significantly improved compared to the control cells, with a t-test value of 0.027 and % increase of 155.2.

[0287] Thus, it can be concluded that the pulsed technology of the present invention significantly increased the transfection efficiency in adherent HCT 116 cells compared to when pulsed technology was not used.

[0288] Experiment 3—Transfection of Suspension HEK 293Freestyle Cells Using the GFP Plasmid and PEI as the Amphiphilic Construct

[0289] This experiment was undertaken to look at the effect of the pulsed technology of the present invention on the process of transfection of Human Embryonic Kidney (HEK) suspension cells 293Freestyle using a green fluorescent protein (GFP) plasmid in a PEI amphiphilic construct. The pulsed technology was applied to the cells and the transfection reagent during the transfection process only.

[0290] Consumables

[0291] Opti-MEM™ I Reduced Serum Media (Thermo Fisher, USA)

[0292] Green Fluorescent Protein (GFP) plasmid (made by Dundee University, UK)

[0293] 293-Freestyle Suspension Cells (Thermo Fisher, USA)

[0294] 293-Free Expression Media (Sigma-Aldrich, USA)

[0295] Alfa Aesar™ Polyethyleneimine, linear, M.W. 25,00 (PEI) (Fisher Scientific, USA)

[0296] Method Steps when Pulsed Technology Used on Reagent and Cell Mixture Only [0297] 1. Seed 6×10.sup.5-7×10.sup.5 293-F cells/mL the day before transfection. [0298] 2. Count the number of cells on the day of transfection and dilute cells if necessary to have a density of 1×10.sup.6 cells/mL [0299] 3. Transfect 15 μg of the Green Fluorescent Protein (GFP) plasmid/flask with 30 μL of 293-Free Expression Media/flask [0300] 4. Use a Ratio of DNA:PEI of 1:2. [0301] 5. Use 293-Free Expression Media following the manufacturer's instructions (https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/SAJ/Brochure/2TB5515.pdf)—User Protocol TB515 Rev. B 0411JN [4] [0302] 6. In order to prepare the DNA-Transfection Mixture: [0303] Add 2.4 mL of Opti-MEM into a flask [0304] Add 30 μg of GFP plasmid to the flask [0305] Add 60 μL of 293-Free Expression Media [0306] Divide the resulting mixture volume into two 125 mL Erlennmeyer flasks, each containing 1×10.sup.6 cells/mL in 28.8 mL of 293 Expression Media; [0307] Incubate the two flasks at 37° C. at 8% CO.sup.2 on a Bellydancer Orbital Shaker (Sigma, Aldrich) at 125 rpm in two separate incubators. Pulse one of the flasks for 3 hours using the Pulsed Technology according to the present invention in one of the incubators and incubate the other flask without any Pulsed Technology in the second incubator. After 3 hours, place both flasks in the same incubator without any Pulsed Technology to allow transfection efficiency to be measured over time for as long as required (120 hours in the case of the experiment).

[0308] Experiment 3 Results

[0309] The transfection efficiency of a GFP plasmid associated with a PEI amphiphilic construct in HEK 293 Freestyle Suspension Cells were measured for controls and pulsed technologies according to the present invention (Pulzar).

[0310] The transfection efficiency (shown by the amount of the mean Green Fluorescence measured) in HEK 293 Freestyle Suspension Cells using pulsed technology was significantly improved compared to the control cells, with a t-test value of less than 0.05 and a peak increase of 2.3 fold more GFP expression was observed.

[0311] The transfection efficiency (shown by amount of the mean Green Fluorescence measured) in HEK 293 Freestyle Suspension Cells using pulsed technology was significantly improved compared to the control cells, with a t-test value of less than 0.05 and an over 50% increase in GFP expression was observed. The delta was calculated to mark the % increase in GFP expression throughout the time period of the experiment.

[0312] Thus, it can be concluded that the pulsed technology of the present invention significantly increased the transfection efficiency in HEK 293 Freestyle Suspension Cells compared to when pulsed technology was not used.

[0313] Experiment 4—Transfection of Suspension Jurkat E6 Cells Using Adluc and Renilla Plasmids and Using Either PEI or TransIT2020 as the Amphiphilic Construct

[0314] This experiment was undertaken to look at the effect of the pulsed technology of the present invention on the process of transfection in Jurkat E6 Cells (Human leukaemic T-Cell lymphoblast cells) (European Collection of Authenticated Cell Cultures (ECACC), UK) using Adluc and Renilla Plasmids in either PEI (Fisher Scientific, USA) or TransIT2020 (Mirus Bio, USA) amphiphilic constructs. The pulsed technology was applied to a) the cells and the transfection mixture (the transfection complex) during the transfection process only; and b) the transfection mixture prior to forming a transfection complex with the cells and then to the transfection complex during the transfection process.

[0315] Consumables

[0316] Opti-MEM™ I Reduced Serum Media (Thermo Fisher, USA)

[0317] Fetal Calf Serum (FCS) (Hyclone, USA)

[0318] RPMI Medium (Sigma-Aldrich, UK)

[0319] 2×24 Well Plates Nunc (1.9 cm.sup.2/well) (Thermo Fisher, USA)

[0320] 1 μg of AdLuc plasmid/well (Luciferase expressing plasmid/DNA) (made by Dundee University, UK)

[0321] 80 ng Renilla plasmid/well (Luciferase expressing plasmid/DNA) (made by Dundee University, UK)

[0322] Alfa Aesar™ Polyethyleneimine, linear, M.W. 25,00 (PEI) (Fisher Scientific, USA)

[0323] TransIT2020 (Mirus Bio, USA)

[0324] Method Steps

[0325] Control—Using PEI

[0326] 1. 650 μL of Opti-MEM media was mixed with 13 μg of AdLuc plasmid and 1 μg of Renilla plasmid in a first tube;

[0327] 2. 650 μL of Opti-MEM media was mixed with 42 μg of PEI in a second tube;

[0328] 3. The contents of the second tube was mixed in a dropwise manner to the first tube while gently vortexing until a final volume of 1.3 mL mixture was achieved using a Vortex-Genie 2, Model G560E, (Scientific Industries, USA);

[0329] 4. The transfection mixture was incubated for 15 minutes at room temperature (approx. 20° C.);

[0330] 5. 100 μL of this incubated transfection mixture was then dispensed into wells labelled A1-A6 on each of the two 24 well plates (Plates 1 and 2). This formed the transfection mixture.

[0331] Invention—with Pulsed Technology Using PEI on Transfection Mixture Prior to Transfection Complex Being Created

[0332] 1. Then, steps 1-3 above were repeated but at step 4—the mixture forming the transfection mixture was incubated for 15 minutes at room temperature (approx. 20° C.) by locating the first tube on a pulsed electromagnetic signal device according to the present invention. The pulsed device operates as described above (i.e. pulsed device operated at 2.45 GHz+/−50 MHz, at power 2 mW using a pulsed frequency of 15 Hz).

[0333] 2. 100 μL of this incubated pulsed transfection mixture was dispensed into wells labelled B1-B6 on each of the two 24 well plates (Plates 1 and 2);

[0334] Control—Using TransIT2020 [0335] 5. 700 μL of Opti-MEM media was mixed with 13 μg of AdLuc plasmid and 1 μg of Renilla plasmid in a first tube; [0336] 6. 42 μL of TransIT2020 was added and mixed by vortexing using a Vortex-Genie 2, Model G560E, (Scientific Industries, USA); [0337] 7. The transfection mixture was incubated for 15 minutes at room temperature (approx. 20° C.) [0338] 8. 50 μL of this incubated transfection mixture was dispensed into wells labelled C1-C6 on each of the two 24 well plates (Plates 1 and 2);

[0339] Invention—Using TransIT2020 with Pulsed Technology on Transfection Mixture Prior to the Transfection Complex being Created [0340] 3. Steps 1-2 above were repeated for the TransIT2020 Control. At step 3—the transfection mixture was incubated for 15 minutes at room temperature (approx. 20° C.) by locating the first tube on a pulsed electromagnetic signal device according to the present invention. The pulsed device operated at 2.45 GHz+/−50 MHz, at power 2 mW using a pulsed frequency of 15 Hz. [0341] 4. 50 μL of this incubated pulsed transfection mixture was dispensed into wells labelled D1-D6 on each of the two 24 well plates (Plates 1 and 2);

[0342] Cell Lines Added to Plates 1 and 2 [0343] For the Plates 1 and 2, a transfection complex was created by adding the Jurkat E6 cells in RPMI and 10% FCS into each well of the two 24 well plates at 2×10.sup.5 cells/well and then made up to a final volume of 600 μL. [0344] Plates 1 and 2 were incubated in an incubator at 37° C., 5% CO.sup.2 overnight; [0345] In plate 1 there was no pulsed technology given to the transfection complex during the overnight incubation stage, whereas plate 2 was subjected to pulsed technology according to the present invention for 3 hours during the overnight incubation stage. [0346] The average value of the three wells for each experimental condition was measured and recorded.

[0347] Luciferase Assay Protocol—Using the Dual-Luciferase Reporter Assay System (Promega, USA)

[0348] Method Steps—as Set Out Above

[0349] Results for Experiment 4

TABLE-US-00006 TABLE 6 Average Luceiferase Pulsed activity Control Technology Luminescence (a.u.) Exp A 15840.33 26452.00 Luminescence (a.u.) Exp B 15840.33 31919.00 Luminescence (a.u.) Exp C 15840.33 35771.67 Exp A - where pulsed technology was applied to the transfection complex only (i.e. once the transfection mixture had been added to the cells and during incubation). Exp B - where pulsed technology was applied to the transfection mixture (prior to adding the Jurkat E6 Cells) only. Exp C - where pulsed technology was applied to the transfection mixture prior to adding the Jurkat E6 Cells) and then also to the transfection complex (i.e. once the transfection mixture had been added to the cells and during incubation).

[0350] Table 6 shows the results of the Jurkat E6 cells experiments for the AdLuc and Renilla Plasmids using the PEI or TransIT2020 amphiphilic constructs and associated methodology.

[0351] With reference to Table 6, each bar on the graph represents an average of 3 replicates. A 1.7 fold increase in transfection efficiency was observed when the transfection complex only received the pulsed technology. A 2.0 fold increase in transfection efficiency was observed when the transfection mixture only received the pulsed technology. A 2.3 fold increase in transfection efficiency was observed when both the transfection mixture and the transfection complex received the pulsed technology. Therefore, it can be concluded that the use of the pulsed technology according to the present invention significant increased transfection efficiency both when used on the transfection mixture or transfection complex alone, but further increases in transfection efficiency were observed when the pulsed technology was applied to both the transfection mixture and the transfection complex.

REFERENCES

[0352] [1] “Transdermal patches: history, development and pharmacology”—Michael N Pastore et al; British Journal of Pharmacology (2015) 172; 2179-2209. [0353] [2]—Gene Therapy—An Industry Corning Of Age—The Cell Culture Dish Inc. 2020 pages 1-49 [0354] [3]—Global Manufacturing of CAR T Cell Therapy—Bruce Levine et al; Molecular Therapy: Methods and Clinical Development, Vol. 4, March 207; 92-101; 2017 Novartis Pharmaceuticals Corp. [0355] [4] Efficient Lipid-Mediated Transfection Of DNA Into Primary Rat Hepatocytes—Sheri L. Holmes et al; In Vitro Cell. Dev. Biol. 30; 347-351—May 1995-1995 Society for In Vitro Biology. [0356] [5] Bourdon et al., Genes Dev. 2005, PMID 16131611. [0357] [6] Longo P A, Kavran J M, Kim M S, Leahy D J. “Transient Mammalian Cell Transfection With Polyethylenimine (PEI). Methods Enzymol. 2013; 529-227-240. Doi:10.1016/B978-0-12-418687-3.00018-5.